BioCentury | Nov 4, 2020
Deals

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

...5 OX1 (HCRTR1) – Orexin 1 receptor (OX1R) OX2 (HCRTR2) – Orexin 1 receptor (OX2R) Amanda...
BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53 skipping. Vyondys golodirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT) was the...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

By enriching its coffers with a further $2.1 billion from existing shareholders, BeiGene gains a formidable cash position as it brings to market a handful of products in the U.S. and China and advances a...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...Phase III trial to treat insomnia. The company plans to submit an NDA for the OX1R/OX2R...
...Targets GNRHR - GnRH/LHRH receptor OX1R (HCRTR1) - Orexin 1 receptor OX2R (HCRTR2) - Orexin 2 receptor...
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

AbbVie’s Genmab deal gives it a ticket to one of the hottest modality spaces, albeit as a latecomer. The pharma gains bispecific antibodies to add to its ADCs and standard mAbs, extending its tool kit...
BioCentury | May 29, 2020
Product Development

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

...market cap slipped to about $145.5 million. Behind roluperidone, Minerva’s pipeline includes seltorexant (MIN-202), an OX2R...
...pivotal study, the ADVANCE-2 trial. Targets 5-HT2A (HT2RA) - Serotonin receptor 2A OX2R (HCRTR2) - Orexin 2 receptor...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

Data from an allogeneic CAR T therapy, bispecific mAbs and new immuno-oncology combinations are some of the highlights expected at the first virtual meeting of the year for the American Association for Cancer Research. Due...
BioCentury | Apr 21, 2020
Product Development

April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

...insomnia patients. The company expects to report data from another Phase III trial of the OX1R/OX2R...
...Cytotoxic T-lymphocyte associated protein 4 OX1R (HCRTR1) - Orexin 1 receptor OX2R (HCRTR2) - Orexin 2 receptor...
...associated protein 4 (CTLA-4) (CTLA4) (CD152) Programmed cell death 1 (PD-1) (PDCD1) (CD279) Orexin 1 receptor (OX1R) (HCRTR1) Orexin 2 receptor (OX2R) (HCRTR2) Parathyroid...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
Items per page:
1 - 10 of 408